Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.

Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC.

Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22.


Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.


A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes.

Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, Sgroi DC.

Clin Cancer Res. 2017 Dec 1;23(23):7217-7224. doi: 10.1158/1078-0432.CCR-17-1688. Epub 2017 Sep 22.


Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stål O, Brufsky AM, Sgroi D, Erlander MG.

Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11.


Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038/bjc.2011.145. Epub 2011 May 10.


Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.

Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O.

Breast Cancer Res. 2010;12(4):R53. doi: 10.1186/bcr2612. Epub 2010 Jul 22.


Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.

Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjöld B, Jansson A, Stål O.

Breast Cancer Res Treat. 2008 Mar;108(1):35-41. Epub 2007 Apr 25.


Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.

Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmström P, Nordenskjöld B, Wingren S, Söderkvist P, Fernö M, Stål O.

Breast Cancer Res Treat. 2008 Jan;107(2):225-34. Epub 2007 Apr 24.


Sulfotransferase1A1 and risk of postmenopausal breast cancer.

Jerevall PL, Ahmadi A, Bergman M, Stål O, Wingren S.

Anticancer Res. 2005 May-Jun;25(3c):2515-7.

Supplemental Content

Loading ...
Support Center